Molecular Targeting Unit, Department of Experimental Oncology, Fondazione IRCCS, Istituto Nazionale Tumori, Milan, Italy.
Breast. 2011 Oct;20 Suppl 3:S63-70. doi: 10.1016/S0960-9776(11)70297-1.
Despite advances in detection and therapies, breast cancer is still the leading cause of cancer death in women worldwide. The etiology of this neoplasm is complex, and both genetic and environmental factors contribute to the complicate scenario. Gene profiling studies have been extensively used over the last decades as a powerful tool to define the signature of different cancers and to predict outcome and response to therapies. More recently, a new class of small (19-25 nucleotides) non-coding RNAs, microRNAs (miRs or miRNAs) has been linked to several human diseases, included cancer. MicroRNAs are involved in temporal and tissue-specific eukaryotic gene regulation,(1) either by translational inhibition or exonucleolytic mRNA decay, targeted through imperfect complementarity between the microRNA and the 3' untranslated region (3'UTR) of the mRNA.(2) Since their ability to potentially target any human mRNA, it is likely that microRNAs are involved in almost every biological process, including cell cycle regulation, cell growth, apoptosis, cell differentiation and stress response.(3) The involvement of microRNAs in the biology of human cancer is supported by an increasing body of experimental evidence, that has gradually switched from profiling studies, as the first breast cancer specific signature reported in 2005 by our group(4) describing an aberrant microRNA expression in different tumor types, to biological demonstrations of the causal role of these small molecules in the tumorigenic process, and the possible implications as biomarkers or therapeutic tools.(5) These more recent studies have widely demonstrated that microRNAs can modulate oncogenic or tumor suppressor pathways, and that, at the same time, their expression can be regulated by oncogenes or tumor suppressor genes. The possibility to modulate microRNA expression both in vitro and in vivo by developing synthetic pre-microRNA molecules or antisense oligonucletides has at the same time provided a powerful tool to a deeper comprehension of the molecular mechanisms regulated by these molecules, and suggested the intriguing and promising perspective of a possible use in therapy. Here we review our current knowledge about the involvement of microRNAs in cancer, focusing particularly on breast cancer, and their potential as diagnostic, prognostic and therapeutic tools.
尽管在检测和治疗方面取得了进展,但乳腺癌仍是全球女性癌症死亡的主要原因。这种肿瘤的病因很复杂,遗传和环境因素都促成了这种复杂的情况。基因谱研究在过去几十年中被广泛应用,作为定义不同癌症特征、预测治疗结果和反应的有力工具。最近,一类新的小(19-25 个核苷酸)非编码 RNA,即 microRNAs(miRs 或 miRNAs),与包括癌症在内的多种人类疾病有关。miRNAs 参与真核生物基因的时间和组织特异性调节,(1)通过翻译抑制或外切核酸酶 mRNA 降解,通过 microRNA 与 mRNA 3'非翻译区(3'UTR)之间的不完全互补性靶向。(2)由于它们有可能靶向任何人类 mRNA,因此 microRNAs 很可能参与几乎所有的生物学过程,包括细胞周期调控、细胞生长、凋亡、细胞分化和应激反应。(3)越来越多的实验证据支持 microRNAs 参与人类癌症的生物学,这些证据逐渐从谱研究转变而来,我们小组于 2005 年首次报道了乳腺癌特异性特征,(4)描述了不同肿瘤类型中异常的 microRNA 表达,到这些小分子在肿瘤发生过程中因果作用的生物学证明,以及作为生物标志物或治疗工具的可能意义。(5)这些较新的研究广泛表明,microRNAs 可以调节致癌或肿瘤抑制途径,同时,它们的表达可以被癌基因或肿瘤抑制基因调节。通过开发合成前 microRNA 分子或反义寡核苷酸来调节 microRNA 表达的可能性,同时为深入了解这些分子调节的分子机制提供了有力的工具,并为治疗中可能的应用提供了诱人的前景。在这里,我们回顾了我们目前对 microRNAs 参与癌症的认识,特别是乳腺癌,以及它们作为诊断、预后和治疗工具的潜力。